12:00 AM
Apr 03, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SuperVent tyloxapol Aerosol Solution: Phase IIa

Preliminary evaluation of DSCO's U.S. Phase IIa trial showed a significant decrease in sputum interleukin-8 (IL-8) levels in 6 CF patients treated...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >